Ampersand Capital Partners

Ampersand Capital Partners is a highly specialized middle-market private equity firm with a singular and dedicated focus on the healthcare sector. Established in 1988, the firm boasts a long and consistent track record of investing in and building leading companies across various segments of healthcare, including outsourced services, diagnostics, life sciences tools, and specialty manufacturing. This deep sector specialization allows Ampersand to leverage extensive industry knowledge and a broad network to identify promising opportunities and support the strategic growth of its portfolio companies.

The firm's investment strategy primarily involves growth equity and buyout transactions, targeting companies with strong fundamentals and significant growth potential. Ampersand distinguishes itself by partnering closely with founders and management teams, providing not only capital but also strategic guidance and operational expertise. Their approach emphasizes driving organic growth, optimizing operational efficiencies, and facilitating strategic add-on acquisitions to create substantial value over their investment horizon.

Ampersand typically deploys significant capital into its portfolio companies. Their equity investments generally range from $20 million to $150 million per transaction, reflecting their focus on established, growing middle-market businesses. The firm has a robust capital base, demonstrated by the successful closing of Ampersand VIII, a fund totaling $1.2 billion, in 2021. This substantial capital allows them to execute complex transactions and provide ample resources for their portfolio companies' expansion initiatives. Their long history and focused strategy underscore their position as a prominent and reliable partner in the healthcare private equity landscape.